Familial Colorectal Cancer
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Familial Colorectal Cancer

What is the definition of Familial Colorectal Cancer?
Familial colon cancer is a cluster of colon cancer within a family. Most cases of colon cancer occur sporadically in people with little to no family history of the condition. Approximately 3-5% of colon cancer is considered "hereditary" and is thought to be caused by an inherited predisposition to colon cancer that is passed down through a family in an autosomal dominant or autosomal recessive manner. In some of these families, the underlying genetic cause is not known; however, many of these cases are caused by changes in the APC, MYH, MLH1, MSH2, MSH6, PMS2, EPCAM, PTEN, STK11, SMAD4, BMPR1A, NTHL1, POLE, and POLD1 genes (which are associated with hereditary cancer syndromes). An additional 10-30% of people diagnosed with colon cancer have a significant family history of the condition but have no identifiable genetic change in a gene known to cause a hereditary predisposition to colon cancer. These clusters of colon cancer are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle.
What are the alternative names for Familial Colorectal Cancer?
  • Familial colorectal cancer
  • Colorectal cancer, familial
Who are the top Familial Colorectal Cancer Local Doctors?
Distinguished in Familial Colorectal Cancer
Hematology | Oncology
Distinguished in Familial Colorectal Cancer
Hematology | Oncology
Referral may be required

Advocate Lutheran General Cancer Institute

1700 Luther Ln 1st & 2nd Fl, 
Park Ridge, IL 
Languages Spoken:
English
Offers Telehealth

Edward James is a Hematologist and an Oncologist practicing medicine in Park Ridge, Illinois. Dr. James is rated as a Distinguished provider by MediFind in the treatment of Familial Colorectal Cancer. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, and Gastrostomy. Dr. James is board certified in American Board Of Internal Medicine, Medical Oncology.

Distinguished in Familial Colorectal Cancer
Distinguished in Familial Colorectal Cancer
Referral may be required

Medical Oncology - Swedish Cancer Institute First Hill

1221 Madison Street, 0, 
Seattle, WA 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Dr. Gold is a multiple time recipient of the Seattle Top Doctor Award and most recently received the 2024 Seattle Magazine Top Doc Award. Dr. Gold is Director of Clinical Research and the Program Leader for the Gastrointestinal (GI) Oncology Program at the Swedish Cancer Institute in Seattle, Washington. In 1991, Dr. Gold obtained his degree in medicine with a distinction in research at the University of Miami School of Medicine in Florida. He then completed an internal medicine internship and residency at the University of Washington. Dr. Gold received the Amgen Oncology Fellowship Award while he was training in medical oncology at the University of Washington School of Medicine and the Fred Hutchinson Cancer Research Center. Presently, he is board certified in medical oncology. Dr. Gold’s clinical investigations on GI tumors, and particularly colorectal cancer treatment, can be found in peer-reviewed publications like the Journal of Clinical Oncology, Seminars in Oncology, and Cancer Investigation. Furthermore, he currently serves as a member of the NCI Colon Task Force, and the Southwest Oncology Group, where he serves as the subcommittee co-chair for colon cancer. In his free time, Dr. Gold enjoys photography and spending time with his wife and three sons. Dr. Gold is rated as a Distinguished provider by MediFind in the treatment of Familial Colorectal Cancer. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Neuroendocrine Tumor, and Lynch Syndrome. Dr. Gold is board certified in American Board Of Internal Medicine. Dr. Gold is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Familial Colorectal Cancer
Hematology | Oncology
Distinguished in Familial Colorectal Cancer
Hematology | Oncology
Referral may be required

Advocate Infusion Center

525 E Congress Pkwy, Ste 300, 
Crystal Lake, IL 
Languages Spoken:
English
Offers Telehealth

Thomas Weyburn is a Hematologist and an Oncologist practicing medicine in Crystal Lake, Illinois. Dr. Weyburn is rated as a Distinguished provider by MediFind in the treatment of Familial Colorectal Cancer. He is also highly rated in 36 other conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Familial Colorectal Cancer. Dr. Weyburn is board certified in American Board Of Internal Medicine, Hematology.

What are the latest Familial Colorectal Cancer Clinical Trials?
Familial Investigations of Childhood Cancer Predisposition

Summary: NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Evaluation of Provider vs. Patient Mediated Cascade Genetic Testing of First-Degree Relatives of Patients With Newly Diagnosed Colorectal Cancer

Summary: This clinical trial compares patient (proband)-mediated communication to provider-mediated communication for improving genetic testing in first-degree relatives of patients with newly diagnosed colorectal cancer. It is estimated that 30% of cases of colorectal cancer have a genetic basis and about 15% of these patients have a disease-causing (pathogenic) inherited (germline) variant in a cancer su...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center